


Heclin

Cat. No.:	HY-110204		
CAS No.:	890605-54-6		
Molecular Formula:	C ₁₇ H ₁₇ NO ₃		
Molecular Weight:	283.32		
Target:	E1/E2/E3 Enzyme; Akt; MyD88		
Pathway:	Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (352.96 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.5296 mL	17.6479 mL	35.2958 mL
		5 mM	0.7059 mL	3.5296 mL	7.0592 mL
10 mM		0.3530 mL	1.7648 mL	3.5296 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Heclin is a HECT E3 ubiquitin ligases inhibitor. Heclin inhibits Smurf2, Nedd4, WWP1 (IC ₅₀ values are 6.8, 6.3, 6.9 μM) and can be used for the research of gastric cancer ^{[1][2][3]} .	
In Vitro	Heclin (10 μM, 1-5 days) inhibits cell viability and IGF1 signaling of BGC803 and MKN45 cell lines ^[1] . Heclin (7 μM, 1 h) ameliorates epinecidin-1-mediated MyD88 degradation in Raw264.7 cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]	
	Cell Line:	BGC803 and MKN45 cells

Concentration:	10 μ M
Incubation Time:	48 h
Result:	Reduced phosphorylation of Akt.

CUSTOMER VALIDATION

- Mol Cell. 2023 Nov 16:S1097-2765(23)00913-9.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wang K, et al. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [J]. *Oncogene*, 2023, 42(14): 1072-1087.
- [2]. Su B C, Chen J Y. Antimicrobial peptide epinecidin-1 modulates MyD88 protein levels via the proteasome degradation pathway [J]. *Marine Drugs*, 2017, 15(11): 362.
- [3]. Mund T, et al. Peptide and small molecule inhibitors of HECT-type ubiquitin ligases [J]. *Proceedings of the National Academy of Sciences*, 2014, 111(47): 16736-16741.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA